Immune biomarkers to predict complications after liver transplantation

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter, prospective observational study will collect serial immune biomarkers from adults undergoing liver transplantation to describe how immune markers change before and after surgery. The study will track associations between biomarker trajectories and post-transplant complications such as infections, acute cellular rejection, hospitalizations, and viral reactivations over 12 months. Biomarkers include cytokines, interferons, immunoglobulins, lymphocyte subsets, monocyte HLA-DR, neutrophil CD64, functional immune assays, checkpoint molecules, and Torque Teno Virus. Blood samples are taken at predefined time points before and after transplant and analyzed for research purposes only, with no changes to immunosuppressive treatment. Clinical outcomes will be collected prospectively at three liver transplant centers in Buenos Aires, Argentina.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Age 18 years or older. Adult patients admitted to the intensive care unit after liver transplantation.

Exclusion Criteria:

Refusal to participate in the study. Liver transplantation performed for acute liver failure (fulminant hepatitis).

Where it's running

• Hospital Universitario Austral
  Pilar, Buenos Aires, Argentina Recruiting
• Hospital Italiano de Buenos Aires
  Buenos Aires, Buenos Aires F.D., Argentina Recruiting
• Hospital Aleman
  Buenos Aires, Buenos Aires F.D., Argentina Recruiting

Study contacts

• Study coordinator: Jorge Martinez, MD
• Email: jorgec.martinez@hospitalitaliano.org.ar
• Phone: +541149590200

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Finding the right steroid dose for acute T cell rejection after kidney or kidney–pancreas transplant

  This trial will test whether lower doses of steroids work as well as higher doses to treat acute T cell–mediated rejection in people who have had a kidney or simultaneous kidney–pancreas transplant.

  Recruiting at 2 sites Phase 3 University of Sydney · Lambton, New South Wales and 29 other locations · NCT06474273

• What the Mayo Clinic is learning from blood clot tests in allergic reactions

  This study tests whether real-time blood clotting markers can help understand and predict the severity of allergic reactions and anaphylaxis in patients 12 and older.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT07905911

• Biomarkers That Signal Silent Strokes in High-Risk Cardiac Procedures

  This study tests whether blood biomarkers NSE and NFLs can predict silent brain injuries and later cognitive problems in adults having high-risk transcatheter heart procedures.

  Recruiting Aristotle University Of Thessaloniki · Thessaloniki · NCT07844850

• Non-invasive test to predict early heart rejection in pediatric transplant patients

  This study tests non-invasive heart tests like cardiac MRI and blood markers to see if they can detect rejection in kids after heart transplant, potentially reducing the need for invasive biopsies.

  Recruiting at 22 sites Vanderbilt University Medical Center · Little Rock, Arkansas and 21 other locations · NCT07770659

• Centenarian cohort in Navarre to study aging and longevity

  This study tests what factors help centenarians in Navarre stay healthier as they age and what might explain their exceptional longevity.

  Recruiting Fundacion Miguel Servet · Pamplona, Navarre · NCT07707297

• Restrictive fluid strategy with phlebotomy during liver transplantation

  This study tests whether a restrictive fluid plan with phlebotomy during liver transplant helps patients recover better than a more fluid-intensive plan.

  Recruiting at 4 sites Centre hospitalier de l'Université de Montréal (CHUM) · Vancouver, British Columbia and 3 other locations · NCT07695363

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.